We examined a panel of HDACi for their ability to upregulate TRAIL-R1 and -R2 on B-CLL cells from cancer patients, and to sensitize those cells to TRAIL-mediated apoptosis. This evidence concerns the gene TNFRSF10A and B-cell chronic lymphocytic leukemia.